Here, we examined the combinatorial effects of treatment with NU7441 plus immune stimulation with IFN-α inducer stimulator of IFN genes (STING) agonist (STGL) and CD40 agonist in murine melanoma models on the infiltration of tumor-reactive effector CD8+ TILs and skewing of the tumor-reactive TCRvβ repertoire. The gene discussed is CD8A; the disease is melanoma.